Replimune

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer.

CEO

Sushil Patel

CEOSushil Patel

Employees

479

Employees479

Headquarters

Woburn, Massachusetts

HeadquartersWoburn, Massachusetts

Founded

2015

Founded2015

Employees

479

Employees479

REPL Key Statistics

Market cap

1.03B

Market cap1.03B

Price-Earnings ratio

-2.37

Price-Earnings ratio-2.37

Dividend yield

—

Dividend yield—

Average volume

41.67M

Average volume41.67M

High today

$7.70

High today$7.70

Low today

$6.65

Low today$6.65

Open price

$6.81

Open price$6.81

Volume

9.77M

Volume9.77M

52 Week high

$17.00

52 Week high$17.00

52 Week low

$2.68

52 Week low$2.68

REPL News

Seeking Alpha 3d

Replimune surges as Cantor upgrades on possible FDA U-turn on lead drug

Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decis...

Analyst ratings

67%

of 9 ratings

Buy

22.2%

Hold

66.7%

Sell

11.1%

People also own

Based on the portfolios of people who own REPL. This list is generated using Robinhood data, and it’s not a recommendation.

Navitas Semiconductor